What type of study is this?

This is a Animal Study study (also classified as: In Vitro Study).

December 8, 2025BloodOpen Access

Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms

View Full Paper

Ask AI

Bookmark

Authors

Preclinical models demonstrate that RMC-7977 enhances ruxolitinib's efficacy, suggesting a new strategy for MPN patients.

RMC-7977 enhances apoptosis and growth inhibition in myeloproliferative neoplasms, indicating its therapeutic potential.
In preclinical studies, RMC-7977 effectively suppressed pERK levels compared to ruxolitinib alone, enhancing treatment response.
Combining RMC-7977 with ruxolitinib improved survival and reduced MPN phenotypes in mouse models, showing promise for patients.
Direct inhibition of RAS may strengthen JAK2 inhibitor therapy, highlighting a novel approach in combating blood cancers.

Pandey et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Preclinical models demonstrate that RMC-7977 enhances ruxolitinib's efficacy, suggesting a new strategy for MPN patients.

RMC-7977 enhances apoptosis and growth inhibition in myeloproliferative neoplasms, indicating its therapeutic potential.
In preclinical studies, RMC-7977 effectively suppressed pERK levels compared to ruxolitinib alone, enhancing treatment response.
Combining RMC-7977 with ruxolitinib improved survival and reduced MPN phenotypes in mouse models, showing promise for patients.
Direct inhibition of RAS may strengthen JAK2 inhibitor therapy, highlighting a novel approach in combating blood cancers.

Pandey et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark